Aderemi Isola Adeyemi, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 214 Beach 92nd St, 1, Rockaway Beach, NY 11693 Phone: 718-634-3727 Fax: 718-835-5008 |
Gerard George Dy Docdocil Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 217 Beach 95 St, Rockaway Beach, NY 11693 Phone: 718-634-9384 Fax: 718-318-8866 |
Universal Physical Therapy Pllc Physical Therapist Medicare: Medicare Enrolled Practice Location: 8624 Rockaway Beach Blvd, Rockaway Beach, NY 11693 Phone: 718-318-6554 Fax: 718-318-7359 |
Vladimir Tokar Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 8400 Shore Front Pkwy Apt. 11n, Rockaway Beach, NY 11693 Phone: 718-380-0555 Fax: 718-380-1511 |
News Archive
A new weapon has emerged to prevent HIV infection. Called pre-exposure prophylaxis, or PrEP, it is a strategy of providing medications to at-risk people before they are exposed to the virus. Having shown great promise in recent phase 3 clinical trials, PrEP may soon be rolled out for public use.
As part of an ongoing and proactive effort to monitor food safety and address contaminants in food, the U.S. Food and Drug Administration today released preliminary data on arsenic levels in certain rice and rice products. The data are part of a larger FDA data collection and analysis about arsenic levels in rice and is based on the first set of approximately 200 samples of rice and rice products collected in the U.S. marketplace.
Aptilon Corporation, a leader in online marketing to physicians and healthcare professionals, today announced its financial results for the three and nine months ended September 30, 2009. Financial references are in CDN dollars unless otherwise indicated. Complete financial statements and MD&A are available on SEDAR at www.sedar.com.
Research carried out at the Peninsula Medical School, South West England, has found strong links between neighbourhood deprivation and the physical and intellectual health of older people.
Amylin Pharmaceuticals and Eli Lilly today announced that the New Drug Application for exenatide has been accepted for review by the Food and Drug Administration.
› Verified 2 days ago